321 related articles for article (PubMed ID: 34100216)
21. Molecular determinants of the interaction between glioblastoma CD133
Shevchenko V; Arnotskaya N; Pak O; Sharma A; Sharma HS; Khotimchenko Y; Bryukhovetskiy A; Bryukhovetskiy I
Int Rev Neurobiol; 2020; 151():155-169. PubMed ID: 32448605
[TBL] [Abstract][Full Text] [Related]
22. SMO-CRISPR-mediated apoptosis in CD133-targeted cancer stem cells and tumor growth inhibition.
Pandey S; Lee M; Lim J; Park S; Choung YH; Kim JE; Garg P; Chung JH
J Control Release; 2023 May; 357():94-108. PubMed ID: 36931470
[TBL] [Abstract][Full Text] [Related]
23. Targeting NFE2L2, a transcription factor upstream of MMP-2: A potential therapeutic strategy for temozolomide resistant glioblastoma.
Rajesh Y; Biswas A; Kumar U; Das S; Banerjee I; Banik P; Bharti R; Nayak S; Ghosh SK; Mandal M
Biochem Pharmacol; 2019 Jun; 164():1-16. PubMed ID: 30885764
[TBL] [Abstract][Full Text] [Related]
24. Anti-CD133 Antibody-Targeted Therapeutic Immunomagnetic Albumin Microbeads Loaded with Vincristine-Assisted to Enhance Anti-Glioblastoma Treatment.
Wang X; Lu P; Zhu L; Qin L; Zhu Y; Yan G; Duan S; Guo Y
Mol Pharm; 2019 Nov; 16(11):4582-4593. PubMed ID: 31573817
[TBL] [Abstract][Full Text] [Related]
25. Improving temozolomide biopharmaceutical properties in glioblastoma multiforme (GBM) treatment using GBM-targeting nanocarriers.
Delello Di Filippo L; Hofstätter Azambuja J; Paes Dutra JA; Tavares Luiz M; Lobato Duarte J; Nicoleti LR; Olalla Saad ST; Chorilli M
Eur J Pharm Biopharm; 2021 Nov; 168():76-89. PubMed ID: 34461214
[TBL] [Abstract][Full Text] [Related]
26. Expression of CD133 and CD44 in glioblastoma stem cells correlates with cell proliferation, phenotype stability and intra-tumor heterogeneity.
Brown DV; Filiz G; Daniel PM; Hollande F; Dworkin S; Amiridis S; Kountouri N; Ng W; Morokoff AP; Mantamadiotis T
PLoS One; 2017; 12(2):e0172791. PubMed ID: 28241049
[TBL] [Abstract][Full Text] [Related]
27. Response of primary glioblastoma cells to therapy is patient specific and independent of cancer stem cell phenotype.
Fouse SD; Nakamura JL; James CD; Chang S; Costello JF
Neuro Oncol; 2014 Mar; 16(3):361-71. PubMed ID: 24311636
[TBL] [Abstract][Full Text] [Related]
28. microRNA expression pattern modulates temozolomide response in GBM tumors with cancer stem cells.
Tezcan G; Tunca B; Bekar A; Preusser M; Berghoff AS; Egeli U; Cecener G; Ricken G; Budak F; Taskapılıoglu MO; Kocaeli H; Tolunay S
Cell Mol Neurobiol; 2014 Jul; 34(5):679-92. PubMed ID: 24691539
[TBL] [Abstract][Full Text] [Related]
29. Modulation of A1 and A2B adenosine receptor activity: a new strategy to sensitise glioblastoma stem cells to chemotherapy.
Daniele S; Zappelli E; Natali L; Martini C; Trincavelli ML
Cell Death Dis; 2014 Nov; 5(11):e1539. PubMed ID: 25429616
[TBL] [Abstract][Full Text] [Related]
30. Proteins of Wnt signaling pathway in cancer stem cells of human glioblastoma.
Shevchenko V; Arnotskaya N; Zaitsev S; Sharma A; Sharma HS; Bryukhovetskiy A; Pak O; Khotimchenko Y; Bryukhovetskiy I
Int Rev Neurobiol; 2020; 151():185-200. PubMed ID: 32448607
[TBL] [Abstract][Full Text] [Related]
31. Novel therapeutics and drug-delivery approaches in the modulation of glioblastoma stem cell resistance.
Smiley SB; Zarrinmayeh H; Das SK; Pollok KE; Vannier MW; Veronesi MC
Ther Deliv; 2022 Apr; 13(4):249-273. PubMed ID: 35615860
[TBL] [Abstract][Full Text] [Related]
32. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide.
Kim SS; Harford JB; Moghe M; Rait A; Pirollo KF; Chang EH
Nucleic Acids Res; 2018 Feb; 46(3):1424-1440. PubMed ID: 29202181
[TBL] [Abstract][Full Text] [Related]
33. Development and Validation of a Targeted Treatment for Brain Tumors Using a Multi-Drug Loaded, Relapse-Resistant Polymeric Theranostic.
Chu W; Houston ZH; Fletcher NL; Huda P; Ahamed M; Lim TX; Day BW; Pinkham M; Thurecht KJ
Biomacromolecules; 2023 Jun; 24(6):2674-2690. PubMed ID: 37143361
[TBL] [Abstract][Full Text] [Related]
34. A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival.
Kim SS; Rait A; Kim E; Pirollo KF; Nishida M; Farkas N; Dagata JA; Chang EH
ACS Nano; 2014 Jun; 8(6):5494-514. PubMed ID: 24811110
[TBL] [Abstract][Full Text] [Related]
35. Tailoring drug co-delivery nanosystem for mitigating U-87 stem cells drug resistance.
Behrooz AB; Vazifehmand R; Tajudin AA; Masarudin MJ; Sekawi Z; Masomian M; Syahir A
Drug Deliv Transl Res; 2022 May; 12(5):1253-1269. PubMed ID: 34405338
[TBL] [Abstract][Full Text] [Related]
36. Tropism of mesenchymal stem cell toward CD133
Pavon LF; Sibov TT; de Souza AV; da Cruz EF; Malheiros SMF; Cabral FR; de Souza JG; Boufleur P; de Oliveira DM; de Toledo SRC; Marti LC; Malheiros JM; Paiva FF; Tannús A; de Oliveira SM; Chudzinski-Tavassi AM; de Paiva Neto MA; Cavalheiro S
Stem Cell Res Ther; 2018 Nov; 9(1):310. PubMed ID: 30413179
[TBL] [Abstract][Full Text] [Related]
37. Temozolomide nanoparticles for targeted glioblastoma therapy.
Fang C; Wang K; Stephen ZR; Mu Q; Kievit FM; Chiu DT; Press OW; Zhang M
ACS Appl Mater Interfaces; 2015 Apr; 7(12):6674-82. PubMed ID: 25751368
[TBL] [Abstract][Full Text] [Related]
38. Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor.
Costa B; Bendinelli S; Gabelloni P; Da Pozzo E; Daniele S; Scatena F; Vanacore R; Campiglia P; Bertamino A; Gomez-Monterrey I; Sorriento D; Del Giudice C; Iaccarino G; Novellino E; Martini C
PLoS One; 2013; 8(8):e72281. PubMed ID: 23977270
[TBL] [Abstract][Full Text] [Related]
39. Temozolomide preferentially depletes cancer stem cells in glioblastoma.
Beier D; Röhrl S; Pillai DR; Schwarz S; Kunz-Schughart LA; Leukel P; Proescholdt M; Brawanski A; Bogdahn U; Trampe-Kieslich A; Giebel B; Wischhusen J; Reifenberger G; Hau P; Beier CP
Cancer Res; 2008 Jul; 68(14):5706-15. PubMed ID: 18632623
[TBL] [Abstract][Full Text] [Related]
40. Intranasal delivery of targeted polyfunctional gold-iron oxide nanoparticles loaded with therapeutic microRNAs for combined theranostic multimodality imaging and presensitization of glioblastoma to temozolomide.
Sukumar UK; Bose RJC; Malhotra M; Babikir HA; Afjei R; Robinson E; Zeng Y; Chang E; Habte F; Sinclair R; Gambhir SS; Massoud TF; Paulmurugan R
Biomaterials; 2019 Oct; 218():119342. PubMed ID: 31326657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
